Compare Stocks

→ Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNF 180 Life Sciences	$1.77 -2.7%	$2.86	$1.33 ▼ $27.93	$1.50M	0.44	106,529 shs	15,531 shs
ATXI Avenue Therapeutics	$0.12 +20.6%	$0.15	$0.09 ▼ $1.25	$5.18M	-0.24	4.61 million shs	9.91 million shs
DFFN Diffusion Pharmaceuticals		$4.64	$2.76 ▼ $7.40	$8.98M	1.78	10,937 shs	351,000 shs
EVOK Evoke Pharma	$0.44 -2.2%	$0.60	$0.42 ▼ $2.40	$3.70M	0.22	53,776 shs	15,641 shs

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNF 180 Life Sciences	-4.21%	-4.71%	-13.75%	-56.06%	-91.29%
ATXI Avenue Therapeutics	-29.63%	-30.20%	-39.16%	-33.31%	-89.63%
DFFN Diffusion Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-22.81%
EVOK Evoke Pharma	+0.90%	-18.49%	-24.15%	-30.83%	-76.93%

Global crypto currency reset (41 major banks signed up) (Ad)

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ATXI Avenue Therapeutics	0.8504 of 5 stars	0.0	5.0	0.0	4.6	1.4	0.0	0.0
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A
ATXI Avenue Therapeutics	3.00	Buy	N/A	N/A
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A
EVOK Evoke Pharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	($0.24) per share	N/A
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	$0.03 per share	N/A
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A	$6.97 per share	N/A
EVOK Evoke Pharma	$5.18M	0.71	N/A	N/A	($0.77) per share	-0.57

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNF 180 Life Sciences	-$19.93M	N/A	0.00	∞	N/A	N/A	-320.26%	-112.07%	5/20/2024 (Estimated)
ATXI Avenue Therapeutics	-$10.38M	-$1.27	N/A	∞	N/A	N/A	N/A	-335.11%	5/10/2024 (Estimated)
DFFN Diffusion Pharmaceuticals	-$15.59M	N/A	0.00	N/A	N/A	N/A	-69.96%	-62.98%	N/A
EVOK Evoke Pharma	-$7.79M	-$2.33	N/A	∞	N/A	-150.43%	-517.99%	-91.83%	5/20/2024 (Estimated)

Latest ATXI, DFFN, ATNF, and EVOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/18/2024	Q4 2023	ATXI Avenue Therapeutics	N/A	$0.56	+$0.56	$0.56	N/A	N/A
3/14/2024	Q4 2023	EVOK Evoke Pharma	N/A	-$0.59	-$0.59	-$0.59	N/A	$1.68 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	N/A
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	N/A
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNF 180 Life Sciences	N/A	0.72	0.72
ATXI Avenue Therapeutics	N/A	1.55	1.55
DFFN Diffusion Pharmaceuticals	N/A	10.71	10.71
EVOK Evoke Pharma	N/A	2.25	2.09

Ownership

Institutional Ownership

Company	Institutional Ownership
ATNF 180 Life Sciences	4.07%
ATXI Avenue Therapeutics	17.34%
DFFN Diffusion Pharmaceuticals	9.95%
EVOK Evoke Pharma	N/A

Insider Ownership

Company	Insider Ownership
ATNF 180 Life Sciences	4.10%
ATXI Avenue Therapeutics	1.80%
DFFN Diffusion Pharmaceuticals	1.80%
EVOK Evoke Pharma	11.78%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNF 180 Life Sciences	5	850,000	818,000	No Data
ATXI Avenue Therapeutics	3	44.26 million	43.46 million	Not Optionable
DFFN Diffusion Pharmaceuticals	13	2.04 million	2.00 million	Not Optionable
EVOK Evoke Pharma	4	8.48 million	7.48 million	Not Optionable

ATXI, DFFN, ATNF, and EVOK Headlines

Source	Headline
	'Like a homecoming': Inizio Evoke Comms welcomes back alum DeViteri as North American president fiercepharma.com - April 23 at 9:26 AM
	Evoke Pharma (NASDAQ:EVOK) Stock Crosses Below 200 Day Moving Average of $0.93 americanbankingnews.com - April 18 at 3:26 AM
	Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com americanbankingnews.com - April 18 at 2:30 AM
	Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications finance.yahoo.com - April 17 at 10:11 AM
	Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications globenewswire.com - April 17 at 8:30 AM
	DelveInsight Business Research, LLP: Gastroparesis Market to Witness Upsurge in Growth at a CAGR of 7% by 2034 \| DelveInsight finanznachrichten.de - April 10 at 7:22 PM
	Empowering students: Innovative approaches to climate change education msn.com - April 10 at 9:21 AM
	Stephanie Carman Joins Underscore Marketing as SVP Client Services; Tiffany Marg Joins Strategy Team finance.yahoo.com - April 10 at 9:21 AM
	How a Dubai man built a $200,000 art collection in his Business Bay home msn.com - April 1 at 9:18 PM
	The Secret Behind Your Soda: The Cocaine-Free Journey of Coca Leaves in Coca-Cola msn.com - March 30 at 10:47 PM
	Brain-Triggered Snacking: A New Understanding of Eating Impulses : ScienceAlert msn.com - March 30 at 7:37 AM
	Evoke Pharma, Inc.: Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer finanznachrichten.de - March 22 at 8:55 AM
	Evoke Pharma Taps Operating Chief D'Onofrio to Succeed CEO Gonyer marketwatch.com - March 21 at 5:34 PM
	Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer finance.yahoo.com - March 21 at 5:34 PM
	Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer globenewswire.com - March 21 at 4:15 PM
	‘Saving animals is ethical, it’s evocative. And it’s smart business’ timesofindia.indiatimes.com - March 19 at 1:56 AM
	Big change is the only constant in eco: India Inc msn.com - March 18 at 10:54 AM
	BU study reveals key to combating high-risk neuroblastoma news-medical.net - March 17 at 8:08 PM
	Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript seekingalpha.com - March 17 at 12:09 AM
	Evoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic? finance.yahoo.com - March 16 at 2:08 PM
	Brain gain: Hope rises with new dementia treatments msn.com - March 15 at 9:08 PM
	Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 15 at 4:06 PM
	Evoke Pharma, Inc.: Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results finanznachrichten.de - March 15 at 11:04 AM
	EVOK Stock Earnings: Evoke Pharma Misses EPS, Beats Revenue for Q4 2023 msn.com - March 15 at 11:04 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

180 Life Sciences

NASDAQ:ATNF

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Avenue Therapeutics

NASDAQ:ATXI

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Diffusion Pharmaceuticals

NASDAQ:DFFN

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.

Evoke Pharma

NASDAQ:EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial